NTRK1 and neoplasm: Targeting NGF with blocking antibodies, or inhibiting the signaling pathways with pharmacological inhibitors against its tyrosine kinase receptor TrkA, has proven to decrease tumor progression and dissemination in animal models by mechanisms involving both the direct inhibition of cancer cell growth [15,19], in addition to tumor innervation, which is essential to cancer progression [17,18].